Cardiac Toxicity
Cardiac toxicity The aim of this scientific session is clearly understanding the mechanism for cardiac toxicity and risk factors. The emergence of various targeted anticancer agents has led cardiotoxic potential. Cardiovascular complication from cancer therapy include heart failure, coronary artery disease, arrhythmias, QT prolongation, valvular disease, arterial hypertension, thromboembolic disease, and peripheral vascular disease. The field of cardiotoxicity induced by targeted drugs is rapidly expanding leading to the evolution of a new subspecialty of cardio-oncology to deal with the new health burden. Heart failure is one of the most dramatic clinical expressions of cardiotoxicity, and it may occur acutely or appear years after treatment. It is imperative for an oncologist to know the toxicity profile of newer agents to lower the risk against the benefit of these agents.
-
Causes of cardiac toxicity -
Clinical symptoms of cardiac toxicity -
Treatment of cardiac toxicity -
Types of cardiac injury